Merck & Company (MRK) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Merck & Company stock price
Merck & Company latest news:
UPDATE 1-Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict
Feb 17 (Reuters) - A federal judge in Delaware has
overturned a jury's verdict requiring Gilead Sciences Inc
to pay a record $2.54 billion because its hepatitis C
drugs Sovaldi and Harvoni infringed a patent held by rival Merck
& Co Inc.
BRIEF-Merck Announces Discontinuation Of APECS Study Evaluating Verubecestat For The Treatment Of People With Prodromal ...
Merck & Co Inc(MRK): * MERCK ANNOUNCES DISCONTINUATION OF APECS STUDY EVALUATING VERUBECESTAT FOR THE TREATMENT OF PEOPLE WITH PRODROMAL ALZHEIMERâS DISEASE.
Merck profit beats on lower taxes, overcoming sales miss
Lower taxes helped U.S. drugmaker Merck & Co (MRK) beat analysts' estimate for fourth-quarter earnings on Friday, offsetting weaker-than-expected sales as some of its products face increasing competition. The drugmaker's shares fell 0.8 percent to $59.35 in early trading.
AstraZeneca is sued by Array BioPharma over cancer drug royalties
Array BioPharma Inc(ARRY) on Thursday sued AstraZeneca AB, accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5 billion collaboration with Merck & Co. In a complaint filed in the New York State Supreme Court in Manhattan, Array is seeking at least $192 million from AstraZeneca (AZN) for the alleged breach of a 2003 licensing agreement relat...
CDC chief bought tobacco stock after taking office: report
Brenda Fitzgerald, President Donald Trump's director of the Centers for Disease Control and Prevention, bought and sold shares in a tobacco company after taking office last year, Politico reported Tuesday, posing a potentially serious conflict of interest. Preventing smoking is a major focus of the CDC. A spokeswoman for the Department of Health and Human Services confirmed the "potentially conflicting" stock purchase to Politico, and said they were made by her financial adviser, and she later sold them. Citing disclosure forms, Politico reported Fitzgerald bought between $1,000 and $15,000 worth of stock in Japan Tobacco Inc. , which owns U.S. brands such as Winston, Camel and Benson & Hedges. She also bought between $1,000 and $15,000 worth of shares in health-care companies Merck & Co. , Bayer and health insurer Humana . Fitzgerald, who took office in July, made the purchases in August and September and sold all her stock holdings by the end of November, Politico reported. Critics called the stock moves "at best, sloppy," at worst "legally problematic," Politico said.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
BRIEF-Merck says First-Time Data For Keytruda In Patients With Previously Treated Advanced Hepatocellular Carcinoma To ...
Merck & Co Inc(MRK): * FIRST-TIME DATA FOR MERCK'S KEYTRUDA® IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA TO BE PRESENTED AT 2018 ASCO GI SYMPOSIUM. * Merck & Co Inc (MRK) - SAFETY PROFILE OF KEYTRUDA WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUSLY REPORTED STUDIES. * Merck & Co Inc (MRK) - SEVEN PATIENTS DISCONTINUED TREATMENT DUE TO TREATMENT-RELATED ADVERSE EVENTS.
Merck leaps past rivals with latest lung cancer drug results
Shares of rivals Bristol-Myers Squibb and Roche drop on the news. Merck& Co. Inc. shares surged 7% in extremely heavy trade Tuesday after the company announced that its key cancer drug Keytruda had positive results in a late-stage clinical trial for advanced lung cancer. Keytruda has already been approved for this indication, last year.
Merck shares jump 7% on news of positive results from lung cancer trial
Merck& Co. Inc. shares jumped almost 7% Tuesday, after the company announced positive results in a late-stage lung cancer trial. The New Jersey-based drug company said the Phase 3 trial of Keytruda in combination with pemetrexed and cisplatin or carboplatin for patients with metastatic non-squamous non-small cell lung cancer met its dual primary endpoints of overall survival and progression-free survival. Results from the Keynote-189 trial will be presented at a coming...
UPDATE: Merck shares jump 7% on news of positive results from lung cancer trial
Merck & Co. Inc. shares jumped almost 7% Tuesday, after the company announced positive results in a late-stage lung cancer trial. The New Jersey-based drug company said the Phase 3 trial of Keytruda in combination with pemetrexed and cisplatin or carboplatin for patients with metastatic non-squamous non-small cell lung cancer met its dual primary endpoints of overall survival and progression-free survival. Results from the Keynote-189 trial will be presented at a coming medical meeting and submitted to the regulator, said Merck. Non-small cell lung cancer is the most common of two types of lung cancer, which kills more people than colon, breast and prostate cancers combined. The news weighed on shares of Roche Holding AG , which is developing a rival drug. Merck shares have fallen about 6% in the last 12 months, while the S&P 500 has gained 22%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
BRIEF-Lycera Corp Announces Initiation Of Phase 1b Study Of Novel Immuno-Oncology Candidate LYC-55716 In Combination ...
Merck & Co Inc(MRK): * LYCERA CORP ANNOUNCES INITIATION OF PHASE 1B STUDY OF NOVEL IMMUNO-ONCOLOGY CANDIDATE LYC-55716 IN COMBINATION WITH PEMBROLIZUMAB Source text for Eikon: Further company coverage:
UPDATE 1-Merck's Keytruda fails pivotal gastric cancer trial
Dec 14 (Reuters) - Merck & Co Inc said on Thursday a
key late-stage trial testing its blockbuster drug, Keytruda,
failed to meet its main goal of extending lives of patients with
a type of gastric cancer.
BRIEF-Merck Says Prevymis To Be Available In Canada By End Of December
* MERCK & CO SAYS RECENTLY APPROVED PREVYMIS (LETERMOVIR) IS
EXPECTED TO BE AVAILABLE IN CANADA BY END OF DECEMBER 2017
Source text for Eikon:
Further company coverage:
BRIEF-Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement
* NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME
AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014
Merck announces $10 billion share buyback
Merck & Co. Inc. announced on Tuesday a $10 billion share buyback program. The company also said that it has increased the quarterly dividend to 48 cents per outstanding share, up one cent from the prior quarter. The dividend, the company's first increase since Nov. 2016, is to be paid to stockholders of record at end of day on Dec. 15. Merck shares were up 0.6% in Tuesday afternoon trade. Shares have dropped 13.4% over the last three months, compared with a 7% rise in the S&P 500 and a 8.4% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Mercury General CorporationMCY
Merrill Lynch & Co.MER^D
Merrill Lynch & Co.MER^E
Merrill Lynch & Co.MER^F
Merrill Lynch & Co.MER^K
Merrill Lynch & Co.MER^M
Merrill Lynch & Co.MER^P